<DOC>
	<DOCNO>NCT02515396</DOCNO>
	<brief_summary>A Phase 1a , randomize , placebo control , two-way crossover study determine effect inhale MMI-0100 compare placebo follow LPS challenge inflammatory marker .</brief_summary>
	<brief_title>Phase 1a Study Healthy Smokers Investigate Effect With MMI-0100 Airway Inflammation Induced Sputum After Challenge With Inhaled Lipopolysaccharide</brief_title>
	<detailed_description>The purpose Phase 1a , randomize , placebo control , two-way crossover study determine effect inhale MMI-0100 compare placebo inflammatory marker follow 5 day daily ( qd ) dose MMI-0100 placebo administer inhalation . On Day 5 treatment period , subject challenge inhaled LPS . Pharmacokinetics biomarkers conduct selected timepoints .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Written sign inform consent Comply study procedure Body mass index ( BMI ) 18 35 kg/m2 inclusive ; minimum body weight 50 kg Male subject : 1 . Subjects female partner childbearing potential must agree use highly effective form birth control , entail use oral , injected hormonal method contraception intrauterine device/system female partner , combination barrier method ( e.g . condom , diaphragm , cervical cap spermicide ) study 3 month discontinuation treatment 2 . Subjects sterilise female partner sterilise 3 . Subjects lifestyle implies abstinence sexual activity study 3 month discontinuation treatment Female subject : 1 . Confirmed postmenopausal woman ( period least one year follicle stimulate hormone ( FSH ) level compliant postmenopausal status accord reference value ) 2 . Subjects agree use highly effective form birth control , entail use oral , injected implant hormonal method contraception intrauterine device/system combination barrier method ( e.g . condom , diaphragm , cervical cap spermicide ) study 3 month discontinuation treatment 3 . For female childbearing potential : female must negative urine pregnancy test screen admission Normal physical examination , laboratory value , 12lead electrocardiogram ( ECG ) vital sign Be current smoker define smoke history ≥10 pack year Ability perform reproducible spirometry Demonstrate FEV1 ≥80 % predict normal Demonstrate evidence airway obstruction Normal airway responsiveness inhaled methacholine Have negative screen serum hepatitis B surface antigen , Hepatitis C antigen human immunodeficiency virus ( HIV ) Be able produce minimum 0.1g sputum induction inhale hypertonic saline Visit 0 Subjects uncontrolled cardiovascular , respiratory , haematologic , immunologic , renal , neurologic , hepatic , endocrine disease , condition might , judgment Investigator , place subject undue risk potentially compromise result interpretation study Any clinically relevant abnormal value physical finding may interfere interpretation study result constitute health risk subject he/she take part study Symptoms , sign laboratory finding suggestive ongoing infective illness time enrolment A history respiratory disease include asthma Donation 1200 mL blood within 12 month Visit 0 , donation blood total &gt; 500 mL within 3 month prior Visit 0 Symptoms clinically significant illness within 2 week pior Visit 0 A significant history alcohol abuse consumption 28 unit ( male ) 21 unit ( female ) alcohol per week A significant history drug abuse ( include benzodiazepine ) positive urine drug abuse test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>